<DOC>
	<DOCNO>NCT02289352</DOCNO>
	<brief_summary>A Randomized , Double-Blind , Multiple-Site , Placebo-Controlled , Parallel-Design Study Evaluate Safety Therapeutic Equivalence Brimonidine Topical Gel , 0.33 % ( Watson Laboratories , Inc. , USA ) Reference Product Mirvaso® ( brimonidine ) topical gel , 0.33 % ( Galderma Laboratories , L.P. , USA ) Patients Moderate Severe Facial Erythema Associated Rosacea</brief_summary>
	<brief_title>Randomized , Double-blind , Multiple-site , Placebo-controlled , Parallel-design Study Patients With Moderate Severe Facial Erythema Associated With Rosacea</brief_title>
	<detailed_description>Up 462 patient 18 year age old , confirm clinical diagnosis rosacea enrol 413 modify intent-to-treat ( mITT ) population 371 per-protocol ( PP ) population . Patients few 3 facial inflammatory lesion , moderate severe erythema accord Clinician 's Erythema Assessment ( CEA ) Patient 's Self-Assessment ( PSA ) .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>1 . Male nonpregnant , nonlactating female , 18 year age old . 2 . Signed informed consent form , meet criteria current FDA regulation . 3 . Females child bear potential must pregnant lactate Screening Randomization ( confirm negative urine pregnancy test sensitivity le 25 mlU/mL equivalent unit human chorionic gonadotropin ) . Women childbearing potential must agree use reliable method contraception ( e.g. , total abstinence , IUD , doublebarrier method [ condom plus diaphragm spermicide ] , oral , transdermal , injected implant non hormonal contraceptive ) , throughout study . A sterile sexual partner consider adequate form birth control . All female consider childbearing potential unless : Are postmenopausal , define woman amenorrheic least 12 consecutive month , without know suspected primary cause . Have sterilize surgically otherwise prove sterile ( i.e. , total hysterectomy , bilateral oophorectomy ) surgery least 4 week prior Screening . Tubal ligation consider surgically sterile method . Female patient childbearing potential define : Women without prior hysterectomy , evidence menses past 12 month . Females amenorrhea ≥ 12 month , amenorrhea possibly due cause , include prior chemotherapy , antiestrogens , ovarian suppression . 4 . Have clinical diagnosis facial rosacea few 3 inflammatory lesion face Screening Randomization ( drug application Day 1 ) . 5 . Have moderate severe facial erythema accord CEA PSA ( i.e. , erythema score 3 CEA PSA ) Screening Randomization ( drug application Day 1 ) . 6 . Free systemic dermatologic disorder ( rosacea ) , opinion Investigator , interfere study evaluation increase risk AEs . 7 . Willing minimize external factor might trigger rosacea flareups ( e.g. , hot environment , prolong sun exposure , strong wind emotional stress ) within 24 hour Screening Randomization visit . 8 . Any skin type race , provide skin pigmentation allow discernment erythema . 9 . Willingness capability cooperate extent degree require protocol . 1 . Patients particular form rosacea ( rosacea conglobata , rosacea fulminans , isolated rhinophyma , isolated pustulosis chin ) concomitant facial dermatosis similar rosacea , perioral dermatitis , demodicidosis , facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus , actinic telangiectasia , present face ( i.e. , 5 area : chin , nose , cheek , forehead ) , opinion Investigator would interfere study evaluation . 2 . Have 3 facial inflammatory lesion rosacea . 3 . Have erythema score 2 ( mild ) , 1 ( almost clear ) , 0 ( clear ) CEA and/or PSA Screening Randomization ( drug application Day 1 ) . 4 . Patients excessive facial hair ( beard , sideburn , mustache , etc . ) would interfere diagnosis assessment rosacea . 5 . Patients moderate severe telangiectasial mass 5 area entire face : forehead , chin , nose cheek , would interfere study evaluation . 6 . History hypersensitivity allergy Mirvaso® include active ingredient brimonidine tartarate component within formulation . 7 . Facial laser surgery telangiectasia ( condition ) within 6 week prior randomization . 8 . Exposed excessive ultraviolet ( UV ) radiation within 1 week screen randomization visit and/or patient unwilling refrain excessive exposure UV radiation course study . 9 . History blood dyscrasia . 10 . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sjögren 's syndrome , depression , condition cause uncontrolled blood flow blood pressure . 11 . Females pregnant , lactate likely become pregnant study . 12 . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation . 13 . Patients severe , unstable uncontrolled cardiovascular disease . 14 . Patients meet study restriction Screening Randomization and/or unwillingness comply restrict treatment 15 . Receipt drug part research study within 30 day dose . 16 . Employees research center Investigator . 17 . Previous participation study . 18 . Patients unable and/or unwilling follow study requirement , procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>